tiprankstipranks
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
US Market

NewAmsterdam Pharma Company (NAMS) Income Statement

Compare
156 Followers

NewAmsterdam Pharma Company Income Statement

Last quarter (Q3 2024), NewAmsterdam Pharma Company's total revenue was $29.11M, an increase of 1450.69% from the same quarter last year. In Q3, NewAmsterdam Pharma Company's net income was $-16.65M. See NewAmsterdam Pharma Company’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 12.76M$ 95.91M$ 0.00$ 0.00
Gross Profit
$ 12.76M$ 95.91M$ 0.00$ 0.00
Operating Expenses
$ 197.06M$ 116.78M$ 36.35M$ 5.40M
Depreciation and Amortization
$ 49.00K$ 8.40K$ 4.39K$ 1.00K
EBITDA
$ -176.86M$ -3.31M$ -30.73M$ -5.43M
Operating Income
$ -165.73M$ -3.32M$ -30.73M$ -5.43M
Other Income/Expenses
$ 5.49M$ -17.58M$ -5.98M$ -320.00K
Pretax Income
$ -160.25M$ -21.14M$ -36.71M$ -5.75M
Net Income
$ -176.94M$ -21.14M$ -36.71M$ -5.75M
Per Share Metrics
$ ―$ ―$ ―$ ―
Basic EPS
$ -2.15$ -1.11$ -3.34$ -1.15
Diluted EPS
$ -2.15$ -1.11$ -3.34$ -1.15
Weighted Average Shares Outstanding
82.16M 18.97M 17.75M 17.75M
Weighted Average Shares Outstanding (Diluted)
82.16M 18.97M 17.75M 17.75M
Currency in USD

NewAmsterdam Pharma Company Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis